The NRAS StripAssay® has been developed to identify a group of mutations in the KRAS and NRAS genes. Effective idenfication of these genes is key to finding the therapies with the greatest chance of success in those suffering from metastatic colorectal cancer. By identifying these mutations monoclonal antibodies that target EGFR can be aoided and a more appropriate course of therapy can be implemented.
NRAS StripAssay® Catalog 5-610
p.G12A (c.35G>C) p.G12C (c.34G>T) p.G12D (c.35G>A) p.G12S (c.34G>A)
p.G12V (c.35G>T) p.G13D (c.38G>A) p.G13R (c.37G>C) p.G13V (c.38G>T)
p.Q61H (c.183A>T) p.Q61K (c.181C>A) p.Q61L (c.182A>T) p.Q61R (c.182A>G)
CYP2D6*3 (2637delA) CYP2D6*4 (193 G>A) CYP2D6*6 (1795delT)